ENTA News and Press, Enanta Pharmaceuticals Inc. From 02/08/21

Broadened Hepatitis B Virus (HBV) Program with EDP-721, a New Oral HBV RNA Destabilizer, as a Potential Component of a Functional HBV Cure Regimen; Plan to Initiate Phase 1 Study Mid-2021 Initiated RSVTx, a Phase 2b Study of EDP-938 in Adult Hematopoietic Cell Transplant Rec...

Enanta Pharma (NASDAQ:ENTA) is scheduled to announce FQ1 earnings results on Monday, February 8th, after market close.The consensus EPS Estimate is -$0.77 and the consensus Revenue Estimate is $27.73M (-47.3% Y/Y).Over the last 1 year, ENTA has beaten EPS estimates 50% of the time and has bea...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its fiscal first quarter ended December 31, 2020 after...

Post JPM Healthcare Conference, the analysts at J.P. Morgan has revised their ratings for stocks in the SMID Biotech space, expecting the companies with a longer timeline for catalysts to trade in line with the group despite a promising outlook expected for biotech in 2021.With a price target...

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced the appointment of Brendan Luu as Senior Vice President, Business Development and member of the company...

The following slide deck was published by Enanta Pharmaceuticals, Inc. in conjunction with this event. For further details see: Enanta Pharmaceuticals (ENTA) Presents at J.P. Morgan Healthcare Conference 2021 - Slideshow

Clinical-stage biotechnology company Enanta Pharmaceuticals ([[ENTA]] -1.2%) talks up its pipeline products ahead of the annual J.P. Morgan Healthcare Conference scheduled next week.The company aims to progress its all-oral, triple regimen that could be a functional cure for patients living w...

Announces New Oral HBV RNA Destabilizer, EDP-721, as an Additional Component Toward Functional HBV Cure; Expects to Initiate Phase 1 Study Mid-2021 Expands RSV Program with Introduction of Discovery Initiative for RSV L-Inhibitors Initiated RSVTx, a Phase 2b Study of...

Brings More Than 30 Years of Clinical Research and Academic Expertise in Respiratory Syncytial Virus Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today a...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will make a formal presentation at the 3...